Evidence map›Paper›PMID 36705415›Full record

ArticleImmunity, inflammation and disease2023

4-1BB and cytokines trigger human NK, γδ T, and CD8

Laurent Vidard

Open access · goldAbstract read
In one paragraph

Article in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. 4-1BB and cytokines trigger human NK, γδ T, and CD8Immunity, inflammation and disease · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Laurent VidardDepartment of Immuno-Oncology, Sanofi, Vitry-sur-Seine, France.ORCID 0000-0001-7484-9187
Sanofi (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study was designed to compare the costimulatory molecules and cytokines required to trigger the proliferation and activation of natural killer (NK), γδ T, and CD8

methodsK562-derived artificial antigen-presenting cells (aAPCs); that is, K562 forced to express CD86 and 4-1BBL costimulatory receptors, in the presence of cytokines, were used to mimic dendritic cells (DCs) and provide signals to support the proliferation and activation of NK, γδ T, and CD8

resultsThree signals are required to trigger optimal proliferation in MART-1-specific CD8

conclusionsTherefore, lymphocytes committed to kill are produced as inactive precursors, and the license to kill is delivered by three signals, allowing for extensive proliferation and effector function acquisition. This data challenges the paradigm of anergy and supports the danger signal theory originally proposed by Polly Matzinger, which states that killer cells are tolerant by default, thereby protecting the mammalian body from autoimmunity.

Indexed as

CD8-Positive T-LymphocytesCytokinesCell ProliferationHumansKiller Cells, NaturalLymphocyte ActivationTumor Necrosis Factor Receptor Superfamily, Member 9CytokinesTNFRSF9 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 94-1BB costimulationactivationCD8+ T cellsIL-15IL-21natural killer cellsproliferationγδ T cells

Identifiers

PMID36705415
PMCPMC9753824
OpenAlexW4311539112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.